Link: ‘Superbug’ firm hires more staff.
Phico has developed a topical SASPject treatment to reduce carriage of the superbug, MRSA, in humans.
MRSA often lives harmlessly in and around the nose of healthy people but can cause a wide range of infections from the trivial to the life threatening, including wound infections and bacteraemia.
It has been demonstrated that reducing the number of MRSA bacteria living on the skin can subsequently lead to a reduction in the number of infections. Phico is also developing an anti-MRSA treatment for intravenous use.
The company plans to start clinical trials in humans in 2005. It has also taken on another lab for production and development work on its next bacterial target, which causes infectious diarrhoea in hospitals and nursing homes.
